{"id":25607,"date":"2026-09-05T02:57:48","date_gmt":"2026-09-05T02:57:48","guid":{"rendered":"https:\/\/thestrategystory.com\/blog\/?p=25607"},"modified":"2026-09-05T03:28:36","modified_gmt":"2026-09-05T03:28:36","slug":"eli-lilly-business-model-2026-how-does-eli-lilly-make-money","status":"publish","type":"post","link":"https:\/\/thestrategystory.com\/blog\/eli-lilly-business-model-2026-how-does-eli-lilly-make-money\/","title":{"rendered":"Eli Lilly Business Model 2026: How Does Eli Lilly Make Money?"},"content":{"rendered":"\n<p>Eli Lilly\u2019s business model in 2026 is built around <strong>discovering or acquiring innovative medicines, moving them through clinical development and regulatory approval, manufacturing them at scale, protecting them through intellectual property, and commercializing them globally through healthcare providers, payers, wholesalers, pharmacies, and increasingly direct-to-patient channels<\/strong>.<\/p>\n\n\n\n<p>Lilly operates as a <strong>single reportable business segment focused entirely on human pharmaceutical products<\/strong>. It discovers, develops, manufactures, markets, and sells medicines worldwide, with products sold in approximately 90 countries.<\/p>\n\n\n\n<p>The model experienced extraordinary expansion in 2025. Revenue increased <strong>45% from $45.0 billion to $65.2 billion<\/strong>, while net income nearly doubled from $10.6 billion to <strong>$20.6 billion<\/strong>.<\/p>\n\n\n\n<p>The biggest driver was Lilly\u2019s cardiometabolic franchise. <strong>Mounjaro generated $23.0 billion and Zepbound $13.5 billion in 2025<\/strong>, meaning the two tirzepatide brands alone accounted for approximately 56% of total company revenue.<\/p>\n\n\n\n<p>Lilly\u2019s business model is therefore increasingly centered on cardiometabolic health, but the company continues investing heavily across oncology, immunology, neuroscience, genetic medicines, and new pharmaceutical platforms to sustain growth beyond its current blockbuster products.<\/p>\n\n\n\n<p>This analysis is based strictly on Eli Lilly\u2019s fiscal 2025 Form 10-K Annual Report.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Industry Background: Why Pharmaceutical Innovation Has High Economic Value<\/h2>\n\n\n\n<p>The pharmaceutical industry solves a fundamental problem: many serious diseases still lack sufficiently effective, safe, convenient, or accessible treatments.<\/p>\n\n\n\n<p>Creating new medicines, however, involves an unusually difficult economic process.<\/p>\n\n\n\n<p>A pharmaceutical company must identify a biological target, discover a potential medicine, conduct laboratory research, progress through several phases of clinical trials, demonstrate safety and efficacy, develop a scalable manufacturing process, obtain regulatory approval, secure reimbursement and patient access, and then educate healthcare professionals about the product.<\/p>\n\n\n\n<p>Lilly describes the development and regulatory process as <strong>extremely costly and potentially capable of significantly delaying product introductions and revenue generation<\/strong>.<\/p>\n\n\n\n<p>Even an approved product still faces significant commercial hurdles.<\/p>\n\n\n\n<p>Competition depends on effectiveness, safety, ease of use, patient preferences, pricing, reimbursement, formulary position, regulatory approvals, marketing effectiveness, and the emergence of competing products or new treatment modalities.<\/p>\n\n\n\n<p>This creates a pharmaceutical business model where enormous amounts of capital are invested years before commercial revenue is certain.<\/p>\n\n\n\n<p>But when a medicine succeeds clinically and commercially, patents and regulatory exclusivity can allow the innovator to generate substantial revenue before generic or biosimilar competition becomes significant.<\/p>\n\n\n\n<p>Lilly\u2019s model is built around repeatedly creating that cycle.<\/p>\n\n\n\n<p><a href=\"https:\/\/thestrategystory.com\/blog\/eli-lilly-business-strategy-2026\/\">Eli Lilly Business Strategy 2026<\/a><\/p>\n\n\n\n<h1 class=\"wp-block-heading\">How Eli Lilly Solves the Problem<\/h1>\n\n\n\n<p>Lilly\u2019s core capability is converting scientific discovery into commercial medicines.<\/p>\n\n\n\n<p>The process can be simplified as:<\/p>\n\n\n\n<p><strong>Scientific research \u2192 drug candidate \u2192 clinical development \u2192 regulatory approval \u2192 manufacturing scale-up \u2192 market access \u2192 commercialization \u2192 lifecycle expansion.<\/strong><\/p>\n\n\n\n<p>The company operates across several major therapeutic areas.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Cardiometabolic Health<\/h2>\n\n\n\n<p>This has become Lilly\u2019s largest business by a wide margin.<\/p>\n\n\n\n<p>Major products include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Mounjaro<\/li>\n\n\n\n<li>Zepbound<\/li>\n\n\n\n<li>Trulicity<\/li>\n\n\n\n<li>Jardiance<\/li>\n\n\n\n<li>insulin products<\/li>\n<\/ul>\n\n\n\n<p>Mounjaro is used in type 2 diabetes, while Zepbound is used for obesity or overweight with certain related conditions and for moderate-to-severe obstructive sleep apnea in adults with obesity.<\/p>\n\n\n\n<p><a href=\"https:\/\/thestrategystory.com\/blog\/eli-lilly-swot-analysis-2026\/\">Eli Lilly SWOT Analysis 2026<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Oncology<\/h2>\n\n\n\n<p>Lilly\u2019s oncology portfolio includes medicines such as:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Verzenio<\/li>\n\n\n\n<li>Jaypirca<\/li>\n\n\n\n<li>Retevmo<\/li>\n\n\n\n<li>Cyramza<\/li>\n\n\n\n<li>Erbitux<\/li>\n\n\n\n<li>Inluriyo<\/li>\n<\/ul>\n\n\n\n<p>These products address breast cancer, lung cancer, leukemia, lymphoma, thyroid cancer, colorectal cancer, and other cancers.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Immunology<\/h2>\n\n\n\n<p>Products include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Taltz<\/li>\n\n\n\n<li>Ebglyss<\/li>\n\n\n\n<li>Omvoh<\/li>\n\n\n\n<li>Olumiant<\/li>\n<\/ul>\n\n\n\n<p>These medicines serve diseases such as psoriasis, rheumatoid arthritis, atopic dermatitis, ulcerative colitis, Crohn\u2019s disease, and alopecia areata.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Neuroscience<\/h2>\n\n\n\n<p>Lilly markets Emgality for migraine and Kisunla for early symptomatic Alzheimer\u2019s disease.<\/p>\n\n\n\n<p>The broad therapeutic portfolio matters because individual medicines eventually face patent expirations, competition, pricing pressure, and changing standards of care.<\/p>\n\n\n\n<p>Lilly therefore needs a continuous flow of new medicines to replace maturing products.<\/p>\n\n\n\n<p><a href=\"https:\/\/thestrategystory.com\/blog\/eli-lilly-pestel-analysis-2026\/\">Eli Lilly PESTEL Analysis 2026<\/a><\/p>\n\n\n\n<h1 class=\"wp-block-heading\">Eli Lilly Business Model<\/h1>\n\n\n\n<p>Lilly formally operates as one reportable segment.<\/p>\n\n\n\n<p>Its global R&amp;D organization discovers and develops medicines, its supply-chain organization manufactures and supplies products, and its commercial organizations market, distribute, and sell them worldwide.<\/p>\n\n\n\n<p>The economic model consists of five interconnected activities:<\/p>\n\n\n\n<p><strong>Discover or acquire medicines \u2192 prove clinical value \u2192 obtain regulatory approval \u2192 manufacture at scale \u2192 monetize through global pharmaceutical sales and partnerships.<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">1. Discover and Develop Medicines Internally<\/h2>\n\n\n\n<p>Internal R&amp;D is the starting point of the model.<\/p>\n\n\n\n<p>Lilly spent <strong>$13.34 billion on research and development in 2025<\/strong>, up 21% from $10.99 billion in 2024.<\/p>\n\n\n\n<p>That R&amp;D spending is divided broadly between:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>R&amp;D Category<\/th><th>FY2025<\/th><\/tr><\/thead><tbody><tr><td>Early-stage R&amp;D<\/td><td>$4.88B<\/td><\/tr><tr><td>Late-stage R&amp;D<\/td><td>$8.46B<\/td><\/tr><tr><td><strong>Total R&amp;D<\/strong><\/td><td><strong>$13.34B<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Early-stage spending primarily covers discovery through Phase 2 trials, while late-stage spending primarily covers Phase 3 clinical development.<\/p>\n\n\n\n<p>Management allocates R&amp;D resources based on factors including:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>probability of technical success,<\/li>\n\n\n\n<li>unmet medical need,<\/li>\n\n\n\n<li>commercial viability,<\/li>\n\n\n\n<li>maintaining a balanced portfolio between near- and long-term opportunities.<\/li>\n<\/ul>\n\n\n\n<p>This shows that Lilly\u2019s R&amp;D model is also a capital-allocation model: the company continually decides which drug candidates deserve further investment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">2. Acquire External Innovation<\/h2>\n\n\n\n<p>Lilly does not rely solely on its internal laboratories.<\/p>\n\n\n\n<p>It also acquires:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>companies,<\/li>\n\n\n\n<li>drug candidates,<\/li>\n\n\n\n<li>technologies,<\/li>\n\n\n\n<li>licenses,<\/li>\n\n\n\n<li>collaborations,<\/li>\n\n\n\n<li>manufacturing capabilities.<\/li>\n<\/ul>\n\n\n\n<p>Management explicitly describes business development as a way to <strong>enhance or refine the pipeline and strengthen the business<\/strong>.<\/p>\n\n\n\n<p>In 2025, acquired in-process R&amp;D charges totaled approximately <strong>$2.91 billion<\/strong>, including transactions involving Scorpion Therapeutics\u2019 STX-478 program and SiteOne Therapeutics.<\/p>\n\n\n\n<p>Lilly also acquired Verve Therapeutics for $549 million net of cash acquired, with potential additional contingent payments. Verve is developing genetic medicines for cardiovascular disease.<\/p>\n\n\n\n<p>The model is therefore:<\/p>\n\n\n\n<p><strong>Internal discovery + external innovation.<\/strong><\/p>\n\n\n\n<p>If a promising scientific platform exists outside Lilly, the company can obtain it rather than needing to invent everything itself.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">3. Protect Medicines Through Intellectual Property<\/h2>\n\n\n\n<p>Patents and regulatory exclusivity are fundamental to pharmaceutical economics.<\/p>\n\n\n\n<p>Lilly states that intellectual-property protection is critical to its ability to commercialize innovation and continue investing in new medicines. Once effective patent protection is lost, branded drugs can experience severe and rapid revenue declines.<\/p>\n\n\n\n<p>For example, Lilly lists Mounjaro\/Zepbound compound patent protection extending to approximately:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>2036 in the U.S.<\/strong><\/li>\n\n\n\n<li><strong>2037 in major European countries<\/strong><\/li>\n\n\n\n<li><strong>2040 in Japan<\/strong><\/li>\n<\/ul>\n\n\n\n<p>This exclusivity period gives Lilly time to earn a return on the enormous cost and risk incurred during drug development.<\/p>\n\n\n\n<p>The basic economic cycle becomes:<\/p>\n\n\n\n<p><strong>Invest heavily before approval \u2192 obtain exclusivity \u2192 scale the successful medicine globally \u2192 generate high gross margins \u2192 reinvest profits into the next generation of drugs.<\/strong><\/p>\n\n\n\n<h1 class=\"wp-block-heading\">How Does Eli Lilly Make Money?<\/h1>\n\n\n\n<p>Lilly generates revenue in two primary ways:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Net product sales<\/strong><\/li>\n\n\n\n<li><strong>Collaboration and other revenue<\/strong><\/li>\n<\/ol>\n\n\n\n<p>In 2025:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Revenue Source<\/th><th>FY2025 Revenue<\/th><th>Approx. Share<\/th><\/tr><\/thead><tbody><tr><td>Net product revenue<\/td><td>$60.96B<\/td><td>93.5%<\/td><\/tr><tr><td>Collaboration &amp; other revenue<\/td><td>$4.22B<\/td><td>6.5%<\/td><\/tr><tr><td><strong>Total<\/strong><\/td><td><strong>$65.18B<\/strong><\/td><td><strong>100%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The overwhelming majority of Lilly\u2019s business therefore comes from selling medicines.<\/p>\n\n\n\n<p>Collaboration revenue includes profit-sharing arrangements, royalties, upfront payments, milestone payments, and revenue associated with product rights.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Mounjaro: Lilly\u2019s Largest Product<\/h2>\n\n\n\n<p>Mounjaro generated approximately <strong>$22.97 billion in 2025<\/strong>, compared with $11.54 billion in 2024\u2014an increase of 99%.<\/p>\n\n\n\n<p>U.S. revenue was $13.65 billion, while revenue outside the U.S. reached $9.32 billion.<\/p>\n\n\n\n<p>International growth was particularly strong, driven primarily by volume as Lilly expanded Mounjaro into major global markets.<\/p>\n\n\n\n<p>Mounjaro alone accounted for roughly <strong>35% of total Lilly revenue<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Zepbound: Rapid Obesity-Market Expansion<\/h2>\n\n\n\n<p>Zepbound generated approximately <strong>$13.54 billion in 2025<\/strong>, up from $4.93 billion in 2024\u2014a 175% increase.<\/p>\n\n\n\n<p>Almost all 2025 Zepbound revenue still came from the U.S.<\/p>\n\n\n\n<p>Together, Mounjaro and Zepbound produced approximately:<\/p>\n\n\n\n<p><strong>$36.5 billion of revenue<\/strong><\/p>\n\n\n\n<p>or roughly:<\/p>\n\n\n\n<p><strong>56% of Lilly\u2019s entire business.<\/strong><\/p>\n\n\n\n<p>Lilly itself highlights that concentration and expects cardiometabolic health to remain a significant and growing part of its future business.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Cardiometabolic Health Is Now the Core Revenue Engine<\/h2>\n\n\n\n<p>Combining U.S. and international revenue, Lilly\u2019s cardiometabolic portfolio generated approximately <strong>$48.2 billion in 2025<\/strong>.<\/p>\n\n\n\n<p>Its components included:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Approx. FY2025 Global Revenue<\/th><\/tr><\/thead><tbody><tr><td>Mounjaro<\/td><td>$22.97B<\/td><\/tr><tr><td>Zepbound<\/td><td>$13.54B<\/td><\/tr><tr><td>Trulicity<\/td><td>$4.28B<\/td><\/tr><tr><td>Jardiance<\/td><td>$3.43B<\/td><\/tr><tr><td>Other cardiometabolic<\/td><td>$4.01B<\/td><\/tr><tr><td><strong>Total Cardiometabolic<\/strong><\/td><td><strong>$48.22B<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Derived from Lilly\u2019s reported U.S. and outside-U.S. revenue tables.<\/p>\n\n\n\n<p>That represents approximately <strong>74% of total company revenue<\/strong>.<\/p>\n\n\n\n<p>This is perhaps the single most important fact for understanding Lilly\u2019s current business model.<\/p>\n\n\n\n<p>It is a diversified pharmaceutical company by therapeutic portfolio, but financially it has become heavily concentrated in cardiometabolic medicine.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Oncology<\/h2>\n\n\n\n<p>Lilly generated approximately <strong>$9.38 billion<\/strong> from oncology products in 2025.<\/p>\n\n\n\n<p>Verzenio contributed approximately <strong>$5.72 billion<\/strong> globally.<\/p>\n\n\n\n<p>Oncology therefore provides an important second earnings engine outside cardiometabolic health.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Immunology<\/h2>\n\n\n\n<p>Immunology generated approximately <strong>$5.25 billion<\/strong> globally.<\/p>\n\n\n\n<p>Taltz alone contributed about <strong>$3.56 billion<\/strong>, with the balance coming from products such as Ebglyss, Omvoh, and Olumiant.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Neuroscience<\/h2>\n\n\n\n<p>Neuroscience generated approximately <strong>$1.39 billion in 2025<\/strong>, including products such as Emgality and Kisunla.<\/p>\n\n\n\n<p>While still relatively small financially, neuroscience provides Lilly with another platform for future portfolio diversification.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\">U.S. Versus International Revenue<\/h1>\n\n\n\n<p>Lilly is a global pharmaceutical company, but the U.S. remains its largest market.<\/p>\n\n\n\n<p>In 2025:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Geography<\/th><th>Revenue<\/th><th>YoY Growth<\/th><th>Share of Total<\/th><\/tr><\/thead><tbody><tr><td>U.S.<\/td><td>$43.48B<\/td><td>43%<\/td><td>~67%<\/td><\/tr><tr><td>Outside U.S.<\/td><td>$21.70B<\/td><td>48%<\/td><td>~33%<\/td><\/tr><tr><td><strong>Total<\/strong><\/td><td><strong>$65.18B<\/strong><\/td><td><strong>45%<\/strong><\/td><td><strong>100%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Interestingly, Lilly\u2019s revenue growth was overwhelmingly volume-driven.<\/p>\n\n\n\n<p>On a consolidated basis:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Volume contributed <strong>+50%<\/strong><\/li>\n\n\n\n<li>Price contributed <strong>-6%<\/strong><\/li>\n\n\n\n<li>Foreign exchange contributed <strong>+1%<\/strong><\/li>\n\n\n\n<li>Net revenue growth was <strong>45%<\/strong><\/li>\n<\/ul>\n\n\n\n<p>This is important because 2025 growth was not primarily driven by raising prices. It came from significantly more patients using products\u2014particularly Mounjaro and Zepbound.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\">How Lilly Sells and Distributes Medicines<\/h1>\n\n\n\n<p>Lilly\u2019s commercial model involves several layers.<\/p>\n\n\n\n<p>The company educates healthcare professionals through direct engagement, digital channels, medical meetings, product information, and sales representatives.<\/p>\n\n\n\n<p>Its account managers work with:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>wholesalers,<\/li>\n\n\n\n<li>pharmacy benefit managers,<\/li>\n\n\n\n<li>insurers,<\/li>\n\n\n\n<li>employers,<\/li>\n\n\n\n<li>managed-care organizations,<\/li>\n\n\n\n<li>group purchasing organizations,<\/li>\n\n\n\n<li>hospitals,<\/li>\n\n\n\n<li>government institutions,<\/li>\n\n\n\n<li>pharmacies.<\/li>\n<\/ul>\n\n\n\n<p>Commercial arrangements frequently involve discounts and rebates.<\/p>\n\n\n\n<p>Most U.S. medicines are distributed through pharmaceutical wholesalers.<\/p>\n\n\n\n<p>The three most important are:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>McKesson<\/li>\n\n\n\n<li>Cencora<\/li>\n\n\n\n<li>Cardinal Health<\/li>\n<\/ul>\n\n\n\n<p>Each accounted for a significant portion of Lilly\u2019s consolidated revenue in 2025.<\/p>\n\n\n\n<p>The financial statements reveal the concentration even more clearly: each of Lilly\u2019s three largest wholesalers represented <strong>between 16% and 24% of consolidated revenue<\/strong>.<\/p>\n\n\n\n<p>This does not necessarily mean those wholesalers are the end consumers. Rather, they function as major distribution channels between Lilly and the healthcare system.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\">LillyDirect Adds a Direct-to-Patient Layer<\/h1>\n\n\n\n<p>One of the more important changes in Lilly\u2019s commercial architecture is <strong>LillyDirect<\/strong>.<\/p>\n\n\n\n<p>LillyDirect is a digital healthcare platform through which selected Lilly medicines can be dispensed by third-party pharmacies and delivered to patients. The platform also provides tools connecting patients with independent healthcare providers and treatment-adherence support.<\/p>\n\n\n\n<p>Lilly states that patient self-pay sales through LillyDirect represented a <strong>growing portion of its business in 2025<\/strong>.<\/p>\n\n\n\n<p>The importance goes beyond simply adding another sales channel.<\/p>\n\n\n\n<p>Traditional pharmaceutical distribution involves:<\/p>\n\n\n\n<p><strong>Manufacturer \u2192 wholesaler \u2192 pharmacy \u2192 patient<\/strong><\/p>\n\n\n\n<p>with insurers and PBMs influencing coverage and economics.<\/p>\n\n\n\n<p>LillyDirect creates an additional access model closer to:<\/p>\n\n\n\n<p><strong>Lilly \u2192 digital platform \u2192 pharmacy\/healthcare partner \u2192 patient<\/strong><\/p>\n\n\n\n<p>This gives Lilly an alternative mechanism to improve access where insurance coverage is limited, particularly in obesity treatment.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\">Payers and Rebates Shape the Real Selling Price<\/h1>\n\n\n\n<p>Pharmaceutical list prices do not equal the revenue Lilly ultimately receives.<\/p>\n\n\n\n<p>The company initially invoices products at contractual prices but records estimated rebates, discounts, patient-assistance costs, returns, Medicaid obligations, Medicare-related rebates, and other concessions as reductions to product revenue.<\/p>\n\n\n\n<p>Health plans and pharmacy benefit managers can therefore have substantial influence over Lilly\u2019s economics.<\/p>\n\n\n\n<p>They negotiate rebates and formulary positioning, while unfavorable placement can restrict patient access through prior authorization, exclusions, higher copays, and other mechanisms.<\/p>\n\n\n\n<p>This explains why pharmaceutical monetization is not simply:<\/p>\n\n\n\n<p><strong>Price \u00d7 prescriptions.<\/strong><\/p>\n\n\n\n<p>It is closer to:<\/p>\n\n\n\n<p><strong>Prescription volume \u00d7 realized net price after rebates, discounts, government programs and payer negotiations.<\/strong><\/p>\n\n\n\n<h1 class=\"wp-block-heading\">Collaboration and Licensing Revenue<\/h1>\n\n\n\n<p>Although product sales dominate Lilly\u2019s business, collaborations provide another monetization mechanism.<\/p>\n\n\n\n<p>Collaboration and other revenue totaled <strong>$4.22 billion in 2025<\/strong>.<\/p>\n\n\n\n<p>These arrangements can include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>shared profits,<\/li>\n\n\n\n<li>royalty revenue,<\/li>\n\n\n\n<li>upfront payments,<\/li>\n\n\n\n<li>development milestones,<\/li>\n\n\n\n<li>sales milestones,<\/li>\n\n\n\n<li>licensing payments,<\/li>\n\n\n\n<li>sales of product rights.<\/li>\n<\/ul>\n\n\n\n<p>For example, Lilly has a collaboration involving Jardiance with Boehringer Ingelheim.<\/p>\n\n\n\n<p>It has licensing arrangements with Roche and Genentech for Ebglyss and with Chugai for orforglipron.<\/p>\n\n\n\n<p>Under the orforglipron agreement, Chugai would receive tiered royalties ranging from mid-single digits to low teens on future worldwide net sales if the product is successfully commercialized.<\/p>\n\n\n\n<p>This allows Lilly to access external science while sharing some future economics with partners.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\">The Economics of Lilly\u2019s Business Model<\/h1>\n\n\n\n<p>Lilly\u2019s 2025 results show the powerful economics of successful patented medicines.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>FY2024<\/th><th>FY2025<\/th><th>Change<\/th><\/tr><\/thead><tbody><tr><td>Revenue<\/td><td>$45.04B<\/td><td>$65.18B<\/td><td>+45%<\/td><\/tr><tr><td>Gross Profit<\/td><td>$36.63B<\/td><td>$54.13B<\/td><td>+48%<\/td><\/tr><tr><td>Gross Margin<\/td><td>81.3%<\/td><td>83.0%<\/td><td>+1.7 pts<\/td><\/tr><tr><td>R&amp;D<\/td><td>$10.99B<\/td><td>$13.34B<\/td><td>+21%<\/td><\/tr><tr><td>Marketing, Selling &amp; Administrative<\/td><td>$8.59B<\/td><td>$11.09B<\/td><td>+29%<\/td><\/tr><tr><td>Net Income<\/td><td>$10.59B<\/td><td>$20.64B<\/td><td>+95%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Gross margin reached <strong>83%<\/strong>, benefiting from favorable product mix and improved production costs despite lower realized pricing.<\/p>\n\n\n\n<p>This highlights the basic economics of pharmaceuticals.<\/p>\n\n\n\n<p>Once a successful medicine has been discovered and manufacturing has been established, the gross profit per unit can be substantial.<\/p>\n\n\n\n<p>But those margins must fund huge expenses elsewhere.<\/p>\n\n\n\n<p>Lilly spent:<\/p>\n\n\n\n<p><strong>$13.3 billion on internal R&amp;D<\/strong><\/p>\n\n\n\n<p>plus:<\/p>\n\n\n\n<p><strong>$2.9 billion on acquired in-process R&amp;D<\/strong><\/p>\n\n\n\n<p>in 2025.<\/p>\n\n\n\n<p>Combined, that represents more than <strong>$16 billion invested in current and future innovation<\/strong>.<\/p>\n\n\n\n<p>The pharmaceutical business model therefore effectively uses profits from today\u2019s blockbuster medicines to fund tomorrow\u2019s pipeline.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\">Manufacturing Capacity Is Becoming a Strategic Constraint<\/h1>\n\n\n\n<p>Successful medicines are only valuable if Lilly can manufacture enough of them.<\/p>\n\n\n\n<p>That became especially important as demand for Mounjaro and Zepbound increased.<\/p>\n\n\n\n<p>Lilly spent approximately <strong>$7.8 billion in capital expenditures in 2025<\/strong>, up from $5.1 billion in 2024, as it invested in global facilities to manufacture existing and future medicines. Management expects meaningfully higher capital spending in the near term.<\/p>\n\n\n\n<p>Lilly has also entered into contract-manufacturing and supply arrangements to expand capacity.<\/p>\n\n\n\n<p>Some agreements related to medicines in development could require payments of up to approximately <strong>$10 billion<\/strong> if Lilly does not purchase specified amounts over contract periods generally extending up to eight years.<\/p>\n\n\n\n<p>This illustrates a major change in the business model.<\/p>\n\n\n\n<p>The traditional pharmaceutical bottleneck was primarily discovering successful drugs.<\/p>\n\n\n\n<p>For Lilly\u2019s incretin franchise, <strong>manufacturing capacity itself has become a critical growth capability<\/strong>.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\">Eli Lilly\u2019s Competitive Advantage<\/h1>\n\n\n\n<p>Lilly\u2019s competitive advantage is built from several interconnected capabilities.<\/p>\n\n\n\n<p>First is <strong>drug discovery and clinical development<\/strong>. The company can invest more than $13 billion annually into R&amp;D and manage candidates across early and late-stage development.<\/p>\n\n\n\n<p>Second is <strong>intellectual property<\/strong>. Patent and regulatory protections create a period during which successful innovation can generate attractive economics.<\/p>\n\n\n\n<p>Third is <strong>manufacturing scale<\/strong>. Lilly is investing billions to ensure that medicines with high demand can actually reach patients.<\/p>\n\n\n\n<p>Fourth is <strong>commercial reach<\/strong>. The company sells medicines across approximately 90 countries and maintains relationships with healthcare professionals, payers, governments, pharmacies, and distributors.<\/p>\n\n\n\n<p>Fifth is <strong>external business development<\/strong>. Lilly can supplement internal R&amp;D through acquisitions, licensing, partnerships, and investments.<\/p>\n\n\n\n<p>Finally, Lilly increasingly benefits from an expanding <strong>cardiometabolic platform<\/strong>.<\/p>\n\n\n\n<p>Mounjaro and Zepbound provide enormous scale today, while candidates such as orforglipron could potentially expand the franchise into additional treatment formats and patient populations.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\">The Biggest Weakness in the Model: Product Concentration<\/h1>\n\n\n\n<p>Lilly\u2019s exceptional growth also creates significant concentration.<\/p>\n\n\n\n<p>Six medicines\u2014Mounjaro, Zepbound, Verzenio, Trulicity, Taltz and Jardiance\u2014collectively generated <strong>82% of total 2025 revenue<\/strong>.<\/p>\n\n\n\n<p>Mounjaro and Zepbound alone generated 56%.<\/p>\n\n\n\n<p>This makes the success of the incretin franchise disproportionately important.<\/p>\n\n\n\n<p>The company is exposed to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>competitor products,<\/li>\n\n\n\n<li>pricing pressure,<\/li>\n\n\n\n<li>reimbursement decisions,<\/li>\n\n\n\n<li>safety concerns,<\/li>\n\n\n\n<li>supply disruptions,<\/li>\n\n\n\n<li>patent challenges,<\/li>\n\n\n\n<li>counterfeit or compounded alternatives,<\/li>\n\n\n\n<li>regulatory actions,<\/li>\n\n\n\n<li>changing patient demand.<\/li>\n<\/ul>\n\n\n\n<p>The stronger Mounjaro and Zepbound become, the greater Lilly\u2019s near-term earnings power\u2014but also the greater its dependence on one scientific platform.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\">Future of Eli Lilly\u2019s Business Model<\/h1>\n\n\n\n<p>The 2025 Annual Report suggests several important directions for the future.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Cardiometabolic Health Will Remain the Primary Growth Platform<\/h2>\n\n\n\n<p>Lilly expects cardiometabolic medicines to remain a significant and growing part of the business.<\/p>\n\n\n\n<p>Mounjaro has now been launched in all major markets, while increased Medicare and Medicaid access could expand the obesity opportunity in the U.S.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Orforglipron Could Extend the Obesity Franchise<\/h2>\n\n\n\n<p>Orforglipron has been submitted for regulatory review in the U.S., EU, and Japan for obesity or overweight and in Europe for type 2 diabetes.<\/p>\n\n\n\n<p>It also received an FDA Commissioner\u2019s National Priority Voucher that could accelerate U.S. review.<\/p>\n\n\n\n<p>This creates an opportunity for Lilly to broaden its cardiometabolic portfolio beyond current products.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Manufacturing Will Continue Expanding<\/h2>\n\n\n\n<p>Additional manufacturing capacity is expected to become operational over the next several years.<\/p>\n\n\n\n<p>Given the magnitude of demand for incretin medicines, manufacturing investment is becoming increasingly linked to revenue growth rather than functioning merely as a supporting activity.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">External Innovation Will Remain Important<\/h2>\n\n\n\n<p>Lilly continues acquiring drug candidates, biotech companies, and technologies.<\/p>\n\n\n\n<p>Its 2025 acquisitions and more than $16 billion of combined internal and acquired R&amp;D spending demonstrate that future growth will come from both Lilly\u2019s laboratories and external science.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\">Conclusion<\/h1>\n\n\n\n<p>Eli Lilly\u2019s business model in 2026 can be summarized as a <strong>pharmaceutical innovation and commercialization engine<\/strong>.<\/p>\n\n\n\n<p>The company:<\/p>\n\n\n\n<p><strong>discovers or acquires promising medicines \u2192 invests billions in clinical development \u2192 obtains regulatory approval \u2192 protects innovation through patents and exclusivity \u2192 manufactures at global scale \u2192 secures access through healthcare providers and payers \u2192 sells medicines globally \u2192 reinvests the resulting cash flows into the next generation of therapies.<\/strong><\/p>\n\n\n\n<p>The economics of this model were exceptionally strong in 2025.<\/p>\n\n\n\n<p>Revenue increased <strong>45% to $65.2 billion<\/strong>.<\/p>\n\n\n\n<p>Net product sales reached <strong>$61.0 billion<\/strong>.<\/p>\n\n\n\n<p>Gross margin increased to <strong>83%<\/strong>.<\/p>\n\n\n\n<p>Net income almost doubled to <strong>$20.6 billion<\/strong>.<\/p>\n\n\n\n<p>And operating cash flow reached <strong>$16.8 billion<\/strong>.<\/p>\n\n\n\n<p>At the center of the model are Mounjaro and Zepbound.<\/p>\n\n\n\n<p>Together they generated approximately <strong>$36.5 billion<\/strong>, or 56% of company revenue, transforming cardiometabolic health into Lilly\u2019s dominant commercial platform.<\/p>\n\n\n\n<p>But Lilly is using the cash generated by today\u2019s successful products to build tomorrow\u2019s portfolio.<\/p>\n\n\n\n<p>It invested $13.3 billion in internal R&amp;D, another $2.9 billion in acquired in-process R&amp;D, and $7.8 billion in capital expenditure during 2025.<\/p>\n\n\n\n<p>The model can therefore be reduced to one continuous cycle:<\/p>\n\n\n\n<p><strong>Science \u2192 clinical evidence \u2192 regulatory approval \u2192 intellectual-property protection \u2192 manufacturing \u2192 patient access \u2192 blockbuster revenue \u2192 reinvestment into science.<\/strong><\/p>\n\n\n\n<p>Lilly\u2019s biggest opportunity is to extend this cycle across obesity, diabetes, oncology, immunology, neuroscience, and new therapeutic technologies.<\/p>\n\n\n\n<p>Its biggest long-term challenge is equally clear: <strong>continue generating new blockbuster medicines before current products lose exclusivity or competitive strength.<\/strong><\/p>\n\n\n\n<p>Source: <a href=\"https:\/\/delivery-p137454-e1438138.adobeaemcloud.com\/adobe\/assets\/urn:aaid:aem:62386fe7-ca4f-49d9-a8b4-7263ba081402\/renditions\/original\/as\/2025_Annual_Report_on_Form_10-K.pdf?assetname=2025_Annual_Report_on_Form_10-K.pdf\">Eli Lilly Annual Report<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Explore Eli Lilly\u2019s business model in 2026 and how it makes money from Mounjaro, Zepbound, oncology, immunology, neuroscience, drug R&#038;D, manufacturing, licensing and LillyDirect.<\/p>\n","protected":false},"author":1,"featured_media":25593,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[166],"tags":[],"class_list":{"0":"post-25607","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business-model"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Eli Lilly Business Model 2026: How Does Eli Lilly Make Money? - The Strategy Story<\/title>\n<meta name=\"description\" content=\"Explore Eli Lilly\u2019s business model in 2026 and how it makes money from Mounjaro, Zepbound, oncology, immunology, neuroscience, drug R&amp;D, manufacturing, licensing and LillyDirect.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/thestrategystory.com\/blog\/eli-lilly-business-model-2026-how-does-eli-lilly-make-money\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly Business Model 2026: How Does Eli Lilly Make Money? - The Strategy Story\" \/>\n<meta property=\"og:description\" content=\"Explore Eli Lilly\u2019s business model in 2026 and how it makes money from Mounjaro, Zepbound, oncology, immunology, neuroscience, drug R&amp;D, manufacturing, licensing and LillyDirect.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/thestrategystory.com\/blog\/eli-lilly-business-model-2026-how-does-eli-lilly-make-money\/\" \/>\n<meta property=\"og:site_name\" content=\"The Strategy Story\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-05T02:57:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-05T03:28:36+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/thestrategystory.com\/blog\/wp-content\/uploads\/2026\/09\/national-cancer-institute-KMvoHcB-w5g-unsplash.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"465\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/thestrategystory.com\/blog\/eli-lilly-business-model-2026-how-does-eli-lilly-make-money\/\",\"url\":\"https:\/\/thestrategystory.com\/blog\/eli-lilly-business-model-2026-how-does-eli-lilly-make-money\/\",\"name\":\"Eli Lilly Business Model 2026: How Does Eli Lilly Make Money? - The Strategy Story\",\"isPartOf\":{\"@id\":\"https:\/\/thestrategystory.com\/blog\/#website\"},\"datePublished\":\"2026-09-05T02:57:48+00:00\",\"dateModified\":\"2026-09-05T03:28:36+00:00\",\"author\":{\"@id\":\"https:\/\/thestrategystory.com\/blog\/#\/schema\/person\/2f78fc259746b58da95619cc4c1a7972\"},\"description\":\"Explore Eli Lilly\u2019s business model in 2026 and how it makes money from Mounjaro, Zepbound, oncology, immunology, neuroscience, drug R&D, manufacturing, licensing and LillyDirect.\",\"breadcrumb\":{\"@id\":\"https:\/\/thestrategystory.com\/blog\/eli-lilly-business-model-2026-how-does-eli-lilly-make-money\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/thestrategystory.com\/blog\/eli-lilly-business-model-2026-how-does-eli-lilly-make-money\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/thestrategystory.com\/blog\/eli-lilly-business-model-2026-how-does-eli-lilly-make-money\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/thestrategystory.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly Business Model 2026: How Does Eli Lilly Make Money?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/thestrategystory.com\/blog\/#website\",\"url\":\"https:\/\/thestrategystory.com\/blog\/\",\"name\":\"The Strategy Story\",\"description\":\"Simplifying Business Strategies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/thestrategystory.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/thestrategystory.com\/blog\/#\/schema\/person\/2f78fc259746b58da95619cc4c1a7972\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/thestrategystory.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/12ad6ed4e2acceb2ca63d603c4f581010634a4b2ec37d408ef885f33d01bac54?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/12ad6ed4e2acceb2ca63d603c4f581010634a4b2ec37d408ef885f33d01bac54?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"http:\/\/thestrategystory.com\/blog\"],\"url\":\"https:\/\/thestrategystory.com\/blog\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eli Lilly Business Model 2026: How Does Eli Lilly Make Money? - The Strategy Story","description":"Explore Eli Lilly\u2019s business model in 2026 and how it makes money from Mounjaro, Zepbound, oncology, immunology, neuroscience, drug R&D, manufacturing, licensing and LillyDirect.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/thestrategystory.com\/blog\/eli-lilly-business-model-2026-how-does-eli-lilly-make-money\/","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly Business Model 2026: How Does Eli Lilly Make Money? - The Strategy Story","og_description":"Explore Eli Lilly\u2019s business model in 2026 and how it makes money from Mounjaro, Zepbound, oncology, immunology, neuroscience, drug R&D, manufacturing, licensing and LillyDirect.","og_url":"https:\/\/thestrategystory.com\/blog\/eli-lilly-business-model-2026-how-does-eli-lilly-make-money\/","og_site_name":"The Strategy Story","article_published_time":"2026-09-05T02:57:48+00:00","article_modified_time":"2026-09-05T03:28:36+00:00","og_image":[{"width":640,"height":465,"url":"http:\/\/thestrategystory.com\/blog\/wp-content\/uploads\/2026\/09\/national-cancer-institute-KMvoHcB-w5g-unsplash.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/thestrategystory.com\/blog\/eli-lilly-business-model-2026-how-does-eli-lilly-make-money\/","url":"https:\/\/thestrategystory.com\/blog\/eli-lilly-business-model-2026-how-does-eli-lilly-make-money\/","name":"Eli Lilly Business Model 2026: How Does Eli Lilly Make Money? - The Strategy Story","isPartOf":{"@id":"https:\/\/thestrategystory.com\/blog\/#website"},"datePublished":"2026-09-05T02:57:48+00:00","dateModified":"2026-09-05T03:28:36+00:00","author":{"@id":"https:\/\/thestrategystory.com\/blog\/#\/schema\/person\/2f78fc259746b58da95619cc4c1a7972"},"description":"Explore Eli Lilly\u2019s business model in 2026 and how it makes money from Mounjaro, Zepbound, oncology, immunology, neuroscience, drug R&D, manufacturing, licensing and LillyDirect.","breadcrumb":{"@id":"https:\/\/thestrategystory.com\/blog\/eli-lilly-business-model-2026-how-does-eli-lilly-make-money\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/thestrategystory.com\/blog\/eli-lilly-business-model-2026-how-does-eli-lilly-make-money\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/thestrategystory.com\/blog\/eli-lilly-business-model-2026-how-does-eli-lilly-make-money\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/thestrategystory.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly Business Model 2026: How Does Eli Lilly Make Money?"}]},{"@type":"WebSite","@id":"https:\/\/thestrategystory.com\/blog\/#website","url":"https:\/\/thestrategystory.com\/blog\/","name":"The Strategy Story","description":"Simplifying Business Strategies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/thestrategystory.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/thestrategystory.com\/blog\/#\/schema\/person\/2f78fc259746b58da95619cc4c1a7972","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/thestrategystory.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/12ad6ed4e2acceb2ca63d603c4f581010634a4b2ec37d408ef885f33d01bac54?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/12ad6ed4e2acceb2ca63d603c4f581010634a4b2ec37d408ef885f33d01bac54?s=96&d=mm&r=g","caption":"admin"},"sameAs":["http:\/\/thestrategystory.com\/blog"],"url":"https:\/\/thestrategystory.com\/blog\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/posts\/25607","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/comments?post=25607"}],"version-history":[{"count":2,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/posts\/25607\/revisions"}],"predecessor-version":[{"id":25616,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/posts\/25607\/revisions\/25616"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/media\/25593"}],"wp:attachment":[{"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/media?parent=25607"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/categories?post=25607"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/tags?post=25607"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}